China Post-marketing Surveillance (PMS) Study of Aldurazyme®

Phase 4

Completed

• Conditions: Mucopolysaccharidosis I
• Interventions: Drug: Laronidase

• Registration Number: NCT05134571
• Lead Sponsor: Genzyme, a Sanofi Company

Brief Summary

This is a single treatment arm study that is open-label to be conducted in Chinese participants with MPS I.

Trial Objectives are to evaluate the safety and tolerability of Aldurazyme in Chinese MPS I participants, and to evaluate the efficacy of Aldurazyme on the percent change of urinary glycosaminoglycans (uGAGs) from baseline to Week 26. The study will also evaluate the effect on uGAG level and liver volume (hepatomegaly) after 26 weeks, with Aldurazyme treatment in Chinese MPS I participants.

Treatment duration will include: 2 weeks of screening, 26 weeks of treatment and 1 week of follow-up period. During the treatment period, weekly visits are designed to accommodate weekly administration of Aldurazyme (laronidase).

Detailed Description

Study duration for each participant will be a total of 29 weeks which will include 2 weeks of screening, 26 weeks of treatment period and 1 week of follow-up period.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2021-10-21
• Study Start: 2021-10-28
• Study First Submitted QC: 2021-11-14
• Study First Posted: 2021-11-26
• Primary Completion: 2023-07-26
• Study Completion: 2023-07-26
• Status Verified: 2023-09
• Last Update Submitted: 2023-09-26
• Last Update Posted: 2023-09-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Chinese participants have a documented diagnosis of MPS I confirmed by measurable clinical signs and symptoms of MPS I and fibroblast or leukocyte IDUA (iduronidase) activity <10% of normal.

• Participants have to be able to stand independently and walk a minimum of 5 meters in 6 minutes.

• A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

  • Is not a woman of childbearing potential (WOCBP).
  • OR
  • Is a WOCBP and agrees to use an acceptable contraceptive method during the intervention period and at a minimum until 7 days after the last dose of study intervention.
  • A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within the screening period before the first dose of study intervention.
  • If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
  • Contraceptive/barrier method is not applicable for male participants.

Read More

Exclusion Criteria

• Prior tracheostomy or bone marrow transplantation or hematopoietic stem cell transplantation.
• Have a plan to undergo bone marrow transplantation or hematopoietic stem cell transplantation within half a year after enrollment.
• Received an investigational drug, or device, other than Aldurazyme, within 30 days prior to study enrollment.
• Received an investigational gene therapy.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Aldurazyme (laronidase)	Laronidase	Aldurazyme (laronidase) treatment at approved dose and regimen, administered every week as an IV infusion

Primary Outcome Measures

Name	Time	Method
Participants with adverse events (AEs)	Baseline to Week 27	Incidence of AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs) including infusion associated reactions (IARs) during the treatment emergent (TE) period
The incidence of Potentially clinically significant abnormality (PCSA) analyses for clinical laboratory, vital signs, and ECG parameters during the TE period	Baseline to Week 27
The percent change of uGAGs	Baseline to Week 26

Secondary Outcome Measures

Name	Time	Method
The percent change of uGAGs	Baseline to Week 2, Week 4, Week 8, Week 12 and Week 20
The absolute change of uGAGs	Baseline to Week 2, Week 4, Week 8, Week 12, Week 20 and Week 26
The percent change of liver volume (Abdominal B type ultrasound examination)	Baseline to Week 26

Trial Locations

Locations (5)

Investigational Site Number :1560001; 🇨🇳 Wuhan, China

Investigational Site Number :1560004; 🇨🇳 Guangzhou, China

Investigational Site Number :1560006; 🇨🇳 Hangzhou, China

Investigational Site Number :1560003; 🇨🇳 Beijing, China

Investigational Site Number :1560002; 🇨🇳 Beijing, China